Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM) announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies. The virtual presentation will be delivered by Thomas Equels, the company's CEO, President & Executive Vice Chairman, on Wednesday, August 20, 2025 at 2:40 PM ET. The event is part of a larger virtual conference taking place from August 19-21, 2025.

AIM ImmunoTech (NYSE American: AIM) announced that its drug Ampligen will be featured in four presentations at the 5th Annual Marie Skłodowska-Curie Symposium in Warsaw, Poland from September 3-5, 2025. The presentations will highlight positive clinical data across multiple areas:

The DURIPANC Phase 2 study shows promising results for pancreatic cancer treatment, with 21% of patients achieving PFS >6 months and 64% reaching OS >6 months. Additional presentations will cover Ampligen's effectiveness in other solid tumors, including ovarian, triple-negative breast, and colorectal cancers.

Notably, analysis of previous clinical trials revealed Ampligen's potential in treating endometriosis, showing approximately 80% symptom improvement in female participants, opening new therapeutic possibilities for this condition affecting 190 million women globally.

AIM ImmunoTech (NYSE American: AIM) has provided an update on its clinical development progress, focusing primarily on Ampligen® (rintatolimod) for pancreatic cancer treatment. The company reported positive mid-year data from its Phase 2 DURIPANC study combining Ampligen® with AstraZeneca's Imfinzi® (durvalumab), showing promising progression-free survival (PFS) and overall survival (OS) with no significant toxicity.

Key achievements include raising $8.0 million through a public equity offering, providing approximately 12 months of operational funding. The company has also secured multiple U.S. patents for Ampligen®, received U.S. and EU Orphan Drug designations for pancreatic cancer, and resumed trading on the NYSE American.

AIM ImmunoTech (NYSE American: AIM) has completed its previously announced public offering, raising $8.0 million in gross proceeds. The offering consisted of 2,000,000 shares of common stock (or pre-funded warrants) along with Class E and Class F warrants at a combined price of $4.00 per share.

The offering included Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with an exercise price of $4.00 per share. Maxim Group LLC served as the sole placement agent for this transaction, which was conducted under an effective S-1 registration statement.

AIM ImmunoTech (NYSE American: AIM) has announced the pricing of a $8.0 million public offering. The offering consists of 2,000,000 shares of common stock (or pre-funded warrants), along with Class E and Class F warrants, priced at $4.00 per share.

The offering includes Class E warrants expiring in 5 years and Class F warrants expiring in 18 months, both with a $4.00 exercise price. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close around July 30, 2025.

AIM ImmunoTech (NYSE American: AIM) has reported positive mid-year data from its Phase 2 DURIPANC study, evaluating the combination of Ampligen® (rintatolimod) with AstraZeneca's Imfinzi® (durvalumab) for treating metastatic pancreatic cancer patients.

The study, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has enrolled 14 out of 25 planned subjects. Key findings include: no significant toxicity, approximately 21% of patients showing PFS >6 months, and 64% of eligible patients achieving OS >6 months. The trial builds on previous successful results of Ampligen as a monotherapy in over 50 pancreatic cancer patients.

AIM has secured intellectual property protection through a U.S. patent extending to 2039 and orphan drug designations in both the U.S. and EU for Ampligen in pancreatic cancer treatment.

AIM ImmunoTech (NYSE American: AIM) announced a presentation at the U.S.-Poland Science and Technology Symposium 2025 featuring Dr. Pawel Kalinski's discussion on the company's drug Ampligen. The presentation, held from June 17-20, 2025, focused on the potential of private-public partnerships in developing oncology treatments.

Dr. Kalinski, a senior investigator for multiple Ampligen oncology studies, highlighted opportunities for expansion in the United States and Eastern European countries through initiatives like the Translational Research Cancer Centers Consortium. CEO Thomas K. Equels will pursue potential clinical partnerships and licensing agreements in Europe, particularly in Poland, at the upcoming Marie Sklodowska-Curie Symposia in September 2025.

AIM ImmunoTech has received a warning notification from NYSE American due to noncompliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has experienced losses in the past five fiscal years. NYSE American requires stockholders' equity of $4.0 million for companies with losses in three of four recent fiscal years, and $6.0 million for those with losses in five recent fiscal years. This follows a previous warning issued in December 2024. AIM has submitted a compliance plan that was accepted by NYSE American, giving the company until June 11, 2026, to meet requirements. The company's stock continues trading under symbol AIM, and the notice does not affect its business operations or SEC reporting requirements.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the resumption of trading of its common stock on the NYSE American exchange effective June 17, 2025. The company's shares are trading under the ticker symbol 'AIM' with CUSIP number 00901B303. The resumption of trading on NYSE American, one of the major U.S. stock exchanges, marks an important milestone for the company's market presence.